SUTRO BIOPHARMA INC. - COMMON STOCK

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

10 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

13 Nov 2024 16:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

04 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

01 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

10 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Sep 2024 16:01:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

14 Sep 2024 03:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

11 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

22 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 May 2024 16:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

30 Apr 2024 08:00:01 By Nasdaq GlobeNewswire

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

02 Apr 2024 06:18:56 By Nasdaq GlobeNewswire

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

25 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in Upcoming Investor Conferences

06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

04 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

14 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

11 Dec 2023 16:05:00 By Nasdaq GlobeNewswire

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

04 Dec 2023 16:05:00 By Nasdaq GlobeNewswire